Fig. 2: Negative predictive value (NPV) of 18F-FDG-PET/CT metabolic non-response and ctDNA detection on D14 to predict early disease progression, after only 3 months of treatment with exemestane-everolimus. | npj Breast Cancer

Fig. 2: Negative predictive value (NPV) of 18F-FDG-PET/CT metabolic non-response and ctDNA detection on D14 to predict early disease progression, after only 3 months of treatment with exemestane-everolimus.

From: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer

Fig. 2

NPV (expressed in %) is displayed below each panel. PFS progression-free survival, NPV negative predictive value; R = 18F-FDG-PET/CT responder; NR = 18F-FDG-PET/CT non-responder; ctDNA = circulating tumor DNA; D-ctDNA detected; ND-ctDNA not detected; D14 = 14 days after starting treatment with exemestane-everolmius.

Back to article page